The metabolomic detection of lung cancer biomarkers in sputum by Cameron, SJ et al.
[ 1 ] 
The metabolomic detection of lung cancer biomarkers in sputum 1 
 2 
Simon J. S. Cameron1, Keir E. Lewis2,3, Manfred Beckmann1, Gordon G. Allison1, Robin Ghosal2, Paul D. Lewis3, 3 
and Luis A. J. Mur1*. 4 
 5 
1Institute of Biological, Environmental and Rural Sciences, Edward Llywd Building, Penglais Campus, 6 
Aberystwyth, Ceredigion, SY23 3FG, UK. 7 
2Department of Respiratory Medicine, Prince Phillip Hospital, Llanelli, SA14 8LY, UK. 8 
3College of Medicine, Swansea University, Swansea, SA2 8PP, UK. 9 
 10 
Running Title: Sputum Metabolomics for Lung Cancer Biomarkers 11 
 12 
* Corresponding Authors: Professor Luis A. J. Mur. Institute of Biological, Environmental and Rural Sciences, 13 
Edward Llywd Building, Aberystwyth University, Penglais Campus, Aberystwyth, Ceredigion, SY23 3FG, Wales, 14 
UK. Phone: 01970 622981. Fax: 01970 622350. Email Address: lum@aber.ac.uk 15 
 16 
 17 
 18 
 19 
 20 
 21 
 22 
 23 
 24 
 25 
 26 
 27 
 28 
[ 2 ] 
Abstract 29 
 30 
Objectives: Developing screening and diagnosis methodologies based on novel biomarkers should allow for the 31 
detection of the lung cancer (LC) and possibly at an earlier stage and thereby increase the effectiveness of clinical 32 
interventions. Here, our primary objective was to evaluate the potential of spontaneous sputum as a source of 33 
non-invasive metabolomic biomarkers for LC status. 34 
 35 
Materials and Methods: Spontaneous sputum was collected and processed from 34 patients with suspected LC, 36 
alongside 33 healthy controls. Of the 34 patients, 23 were subsequently diagnosed with LC (LC+, 16 NSCLC, six 37 
SCLC, and one radiological diagnosis), at various stages of disease progression. The 67 samples were analysed 38 
using flow infusion electrospray ion mass spectrometry (FIE-MS) and gas-chromatography mass spectrometry 39 
(GC-MS).  40 
 41 
Results: Principal component analysis identified negative mode FIE-MS as having the main separating power 42 
between samples from healthy and LC. Discriminatory metabolites were identified using ANOVA and Random 43 
Forest.  Indications of potential diagnostic accuracy involved the use of receiver operating characteristic / area 44 
under the curve (ROC/AUC) analyses. This approach identified metabolites changes that were only observed 45 
with LC.  Metabolites with AUC values of greater than 0.8 which distinguished between LC+/LC- binary 46 
classifications where identified and included Ganglioside GM1 which has previously been linked to LC.  47 
 48 
Conclusion: This study indicates that metabolomics based on sputum can yield metabolites that can be used as 49 
a diagnostic and/or discriminator tool. These could aid clinical intervention and targeted diagnosis of LC within 50 
an ‘at risk’ LC- population group. The use of sputum as a non-invasive source of metabolite biomarkers may aid 51 
in the development of an at-risk population screening programme for lung cancer or enhanced clinical diagnostic 52 
pathways. 53 
 54 
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1 Introduction 57 
 58 
Lung cancer (LC) is the most prevalent cancer in the world; responsible for 1.3 million deaths annually [1]. The 59 
last 30 years has seen little improvement in the overall five year survival rate for LC; with only 15% of patients 60 
living for at least five years after their initial diagnosis [2]. These relatively poor survival rates are primarily a 61 
result of the late detection of a malignancy; reducing the success of clinical interventions. Clinicians currently 62 
rely on three main tools for LC diagnosis: X-ray, computerised tomography (CT) scans, and bronchoscopy. These 63 
methods have improved our ability to detect lung cancer, but have nevertheless failed to improve the rate of 64 
early LC detection [3]. Another aspect of this poor early detection is the association of LC with smoking, which 65 
masks some of the disease’s early symptoms, which has been linked to approximately 90% of LC tumours [4] .  66 
 67 
An alternative screening methodology to radiography, which is currently the most widely used approach, is the 68 
utilisation of molecular markers, both genetic and metabolomic, in biofluids. For example, microRNAs have been 69 
suggested as biomarkers for NSCLC in sputum [5], plasma [6], and serum [7]. Previous work by members of this 70 
research group has demonstrated that chemometric analysis combined with Fourier transform infrared 71 
spectroscopy is a non-invasive approach that allows for the discrimination of LC positive patients. This 72 
demonstrated that sputum could be used as a non-invasive source of biomarkers for LC [8]. However, analysis 73 
of mid-IR spectra only provides information on broad changes in classes of chemicals, and has a poor ability to 74 
resolve changes to particular chemicals. By comparison, metabolite profiling based on sample screening using 75 
Mass Spectrometry (MS) can resolve changes in individual chemicals and thus, could more readily identify 76 
biomarkers linked to LC detection.  77 
 78 
The aim of this study was to employ MS metabolomic profiling to identify clinically relevant biomarkers in 79 
sputum that could be used for detect LC (diagnosis) as well as provide some pathophysiological insights based 80 
on the characteristics of the chemical biomarkers. We utilised two MS approaches in this study, Gas 81 
Chromatography MS (GC-MS) and Flow Infusion Electrospray MS (FIE-MS). Our rationale for this approach is that 82 
both MS technologies are widely used in biomarker discovery, but have differing levels of sensitivities and 83 
different approaches in regards to sample preparation and analysis. For example, GC-MS requires chemical 84 
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derivatization of sample metabolites prior to analysis whilst FIE-MS requires no pre-treatment [9]. Although, our 85 
study employed both univariate and multivariate approaches our study sought to conform to the demands of 86 
the TRIPOD (The Transparent Reporting of a multivariable prediction model for Individual Prognosis Or 87 
Diagnosis) Statement by adhering to the recommended checklist [10]. We employed assessments of diagnostic 88 
accuracy based on receiver operating characteristic (ROC)/ Area under the Curve (AUC) that suggest that our 89 
approach could be used in clinical context to inform the detection of the disease.  To the best of our knowledge, 90 
metabolomic profiles have not been reported using sputum as a biofluid from clinical patients. Thus, beyond, 91 
the detection of biomarkers, a description of the LC sputum metabolome offers a novel insight into the 92 
pathology of LC.  93 
 94 
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 99 
 100 
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 110 
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2 Materials and Methods 114 
 115 
2.1 Ethics Statement 116 
The MedLung observational study (UKCRN ID 4682) received loco-regional ethical approval from the Hywel Dda 117 
Health Board (05/WMW01/75). Written informed consent was obtained from all participants at least 24 hours 118 
before sampling, at a previous clinical appointment, and all data was link anonymised before analysis.  119 
 120 
2.2 Study Design 121 
This study aimed to compare the metabolomes of three groups of sputum samples. Two sets of sputum samples 122 
were obtained from patients referred to the access LC clinic at the Prince Phillip Hospital, Wales, UK; a site of 123 
primary care.  Lung cancer status was subsequently assessed as part of the Medlung observational study (UKCRN 124 
ID 4682) and patients were classified as either LC+ or diagnosed with another pulmonary disease (LC-) based on 125 
histological assessments of sputum bronchoscopy derived samples (Table S1). Metadata including 126 
comorbidities, smoking history and drug history are given in Table S1.  Additionally, spontaneous sputum 127 
samples were collected from staff members at Swansea University who had no previous history of cancer or 128 
lung disease, other than asthma. These non-clinical samples were designated as a control (CON) group. The 129 
design expensively exploited pair-wise analyses between LC+ and LC- groups and the CON group.  As this project 130 
was seen as a pilot project, no external validation set, comprising, for example, testing on another set of patients 131 
samples was used. Further, the danger of over-fitting the derived data was reduced through the extensive use 132 
of simple two-way ANOVA in our pairwise comparisons.   Sampling occurred between 2012-2013 to align with 133 
the Medlung study timeline and this, rather than an a priori design target, governed the number of samples 134 
analysed.   135 
 136 
2.3 Patient Recruitment and Sampling 137 
Spontaneous sputum was collected from referrals to our rapid access LC clinic at the Prince Phillip Hospital, 138 
Wales, UK or volunteers from staff members at Swansea University. No a priori criteria were applied to the 139 
selection of patients or volunteers other than their ability to produce sputum.  Patients were asked to cough 140 
into sterile, 50 mL polypropylene tubes (Greiner Bio-One Ltd, UK) prior to bronchoscopy, to at total volume of 141 
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2-3 mL. A 100 L aliquot of all samples, including the CON group, was taken to create a second pellet that was 142 
subsequently formalin fixed and wax embedded prior to sectioning and staining with haemotoxylin and eosin 143 
(H&E). To confirm samples were of bronchial origin, H&E stained sections were assessed by a consultant 144 
histopathologist for presence of bronchial epithelial cells.  Histological assessments of the LC+ class allowed the 145 
recording of LC type and stage. Thus, NSCLC classifications were obtained for sixteen samples and six were SCLC. 146 
Only in one case (LC06) was no classification obtained.  Within the NSCLC samples, seven could be sub-classified 147 
as adenocarcinoma type and five squamous cell types.  Considering the LC- classified samples, three were 148 
diagnosed with chronic obstructive pulmonary disease (COPD) and two with pneumonia. Amongst the LC+ group, 149 
only two (LC07, LC20) were diagnosed with COPD which could be considered a LC co-morbidity and none with 150 
pneumonia.  151 
 152 
2.4 Processing of Raw Sputum 153 
In line Raw sputum samples were frozen at -80 °C and defrosted in ice for approximately two hours when 154 
required. Sputum cells were isolated by adding 0.5 mL of a working solution of dithiothreitol (DTT), made up by 155 
adding 2.5 g of DTT to 31 mL of 30% aqueous methanol, and 5 mL of 30% aqueous methanol. The samples were 156 
then placed on a vortex mixer for 15 minutes and underwent centrifugation at 1,800 x g for 10 minutes. The 157 
supernatant was removed and the pellet used in subsequent metabolomic profiling. 158 
  159 
2.5 Flow Infusion Electrospray Mass Spectrometry (FIE-MS) 160 
After processing, 20 µL of the sputum pellet was added to 20 µL of ultrapure water and 40 µL of ice-cold HPLC 161 
grade acetone. Samples were vortex mixed for five seconds, cooled on ice for 30 minutes, and then underwent 162 
centrifugation at 11,000 x g for five minutes. After centrifugation, 50 µL of the supernatant was removed and 163 
250 µL of 70% methanol (made up using HPLC grade methanol and ultrapure water) was added. Glass vials were 164 
capped and analysed in random order on a LTQ linear ion trap (Thermo Electron Corporation). Data were 165 
acquired in alternating positive and negative ionization modes over 4 scan ranges (15–110, 100–220, 210–510, 166 
and 500–1200 m/z), with an acquisition time of five minutes. The resulting mass spectrum was the mean of 20 167 
scans about the apex of the infusion profile.  168 
 169 
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2.6 Gas Chromatography Mass Spectrometry (GC-MS) 170 
The sputum pellet was processed as described in section 2.4 and 50 µL of the supernatant after centrifugation 171 
removed and dried using a DNA SpeedVac (Savant, USA) at 40°C. After removal of all liquid, 30 µL of a 20 mg/ml 172 
solution of methoxyamine dissolved in pyridine was added and each sample was transferred to a 11 mm 173 
diameter glass GC vials which were capped with Teflon crimp caps and incubated at 90°C for 15 minutes. After 174 
cap removal, 20 µL of N,O-Bis(trimethylsilyl)trifluoroacetamide (BSTFA) was added to the sample, alongside 5 175 
µL of an alkane standard mix. This mixture comprised of C10, C13, C15, C18, C19, C23, C28, C32 and C36 alkanes dissolved 176 
in pyridine each at a concentration of 2 µL/mL (for alkanes liquid at room temperature) or 2 mg/mL (for alkanes 177 
solid at room temperature). The vials were recapped and incubated at 90°C for 15 minutes. Samples were 178 
analysed by duplicate injection on a 6890N GC linked to a 5973N mass analyser and a 7683 auto-sampler (Agilent 179 
Technologies) fitted with a Thermo Scientific TR-Pesticide II fused silica column (30m x 0.25 mm ID x 0.25 µm 180 
film thickness). Helium carrier gas was supplied at a constant flow rate of 1 mL per minute and following the 181 
injection of 1 µl of sample the GC oven was held at 80°C for three minutes, increased to 280°C at a rate of 15°C 182 
per minute, and then to 330°C at a rate of 50°C per minute. The inlet temperature was 280°C and samples were 183 
split with a 2:1 split ratio. The temperature of the MS transfer line was 330°C.  184 
 185 
2.7 Accurate Mass Determination 186 
Selected discriminatory nominal mass signals were investigated further by targeted nano-flow Fourier 187 
Transform-Ion Cyclotron Resonance Ultra-Mass-Spectrometry (FT-ICR-MS) using TriVersa NanoMate (Advion 188 
BioSciences Ltd) on a LTQ-FT-ULTRA (Thermo Scientific) to obtain ultra-high accurate mass information and MSn 189 
ion-trees [11]. Resulting accurate mass values were used to interrogate the Human Metabolome Database [12]. 190 
Based on an accuracy of 1 ppm for the FT-ICR-MS, the top ranking metabolite with this range indicated as the 191 
identification for each discriminatory negative ionisation mode FIE-MS metabolite. 192 
 193 
2.8 Data and Statistical Analysis 194 
All GC-MS data pre-treatment procedures, including baseline correction, chromatogram alignment, and data 195 
compression were performed by using custom scripts in Matlab version 6.5.1 (The Math Works Inc). Targeted 196 
peak lists were generated, and peak apex intensities of each characteristic mass in a retention time window 197 
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were saved in an intensity matrix (run x metabolite). FIE-MS data was normalised with the total ion count for 198 
each sample used to transform the intensity value for each metabolite in to a percentage of the total ion count, 199 
after the removal of metabolites below 50 m/z. Principal Component Analyses (PCA).  Briefly, this involves 200 
projecting a (“X”) matrix formed from set of (N) spectra with a given mass range (p) (i.e. a N x p matrix) onto 201 
multi-dimensional space. Principal components (PC) are linear combinations of original variables (known as 202 
loadings) which are used in the projection of the X matrix. Individual PCs are ranked (PC1, PC2…etc) on the basis 203 
of the variance within the original data-set that is explained. PCA is an unsupervised method where no a priori 204 
knowledge of experimental structure is given. Thus, if there is clustering of either 2D or 3D projections of PCA 205 
from replicate data this indicates that the original experimental parameters are the sources of maximal 206 
variation. Hierarchical Cluster Analyses (HCA) with heat maps, and Random Forest (RF) multivariate analysis 207 
were completed using the PyChem (Version 3.0.5g Beta) package [13] and/or MetaboAnalyst 2.0 [14]. ROC 208 
(Receiver Operating Characteristic) curve analyses plot the true positive rate (Sensitivity) in function of the false 209 
positive rate (Specificity) and the validity of the fit is indicated based on area under curve (AUC) calculations. 210 
ROC-AUC analyses used the ROC Curve Explorer and Tester (ROCCET) online platform [15] to assess our standard 211 
binary classification tests.  Due to the exploratory nature of this pilot study, no external validation set consisting 212 
of an independent population of samples was available to be included in (e.g.) the ROC analyses.  213 
 214 
 215 
 216 
 217 
 218 
 219 
 220 
 221 
 222 
 223 
 224 
 225 
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3 Results  226 
 227 
Patients and participants sampled as part of this study are summarised in Table 1, with individual sample data 228 
in Supplementary Tables 1a and 1b. A total of 34 patients with suspected LC were recruited, with 23 confirmed 229 
with LC (LC+) (16 NSCLC (nine Stage 4, three Stage 3A, one Stage 3B, three Stage 2B, and one Stage 1B), six SCLC 230 
(three extensive and three limited), and one receiving a clinic-radiological diagnosis made by the LC 231 
multidisciplinary team), and 11 had no diagnosis of LC after extensive testing and follow up for at least one year 232 
(LC-). In addition, a total of 33 non-clinical controls (CON) were collected from participants with no history of 233 
clinical lung disease. 234 
 235 
Metabolomic profiles of the sputum samples were acquired using FIE-MS (in negative and positive ionization 236 
modes) and GC-MS platforms and analysed using PCA. Both MS platforms were examined as although GC-MS is 237 
widely employed in metabolomics profiling, it lacks the sensitivity of FIE-MS and thus, the latter could yield a 238 
more comprehensive data set [16]. PCA indicated that the metabolomic profile acquired in negative ionisation 239 
FIE-MS mode (Figure 1a) showed the greatest degree of separation between the three sample groups (LC+/LC-240 
/CON). Such a separation was not evident in positive FIE-MS mode (Figure 1b), and only partially exhibited in 241 
the analyses of the GC-MS profiles (Figure 1c) suggestive of the value of the greater sensitivity of the FIE-MS 242 
approach and platform. The FIE-MS— metabolites were then analysed using one-way ANOVA which identified 243 
the top 25 metabolites based on their discriminatory ability whose levels significantly differed between the 244 
sample groups. Derivation of a HCA with heat map based on these top 25 metabolites also demonstrated that 245 
the LC+ and LC- could be readily separated from the CON group (Figure 2). Furthermore, many LC+ samples 246 
clustered together. 247 
 248 
Whilst simple analyses such as PCA or ANOVA could distinguish between the LC+/LC- class and CON, supervised 249 
analyses, where a priori information of the sample classes was required, would be need to identify variable 250 
between the LC+ and LC- classes. Due to the separation shown with FIE-MS- metabolites into clinically relevant 251 
classes these datasets were used to identify clinical relevant metabolomic biomarkers. Random Forest (RF) 252 
analyses were then used to indicate a number of metabolites which differentiated between the experimental 253 
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classes (Figure 3). Metabolites which were either increased or decreased in the LC+ or CON classes compared to 254 
the LC- class which were taken forwards to identification by high resolution MS.  255 
 256 
ROC -AUC analyses were also used to identify discriminatory metabolites. The top five metabolites for each 257 
differential comparison are listed in Table 2 with the AUC figure and box and whisker distributions of the data 258 
for the top differential metabolites shown in Figure 4. t-tests of the targeted metabolites indicated a high level 259 
of significance in each comparison. These identified a number of metabolites that had a high AUC value (>0.99) 260 
for differentiating between non-clinically (CON- class) and clinically acquired (LC-/LC+ classes) samples. Four 261 
metabolites were identified with an AUC value of greater than 0.80, a threshold for clinically useful prediction.   262 
 263 
To identify the mass-ions targeted by RF and ROC-AUC analyses, high resolution MS using FT-ICR-MS was 264 
employed. Metabolites were identified, where possible, based on this accurate mass profiling and database 265 
interrogations, (Table 3) and these were used to annotate the analyses shown in Figures 3 and 4. Examination 266 
of the metabolites listed in Supplementary Table 2 includes those involved in polyamine (putrescine), amino 267 
acid, and lipid metabolism. Clinical samples (LC+/LC-) appeared to be separated from CON sample through 268 
differential processing of polyamine metabolites; putrescine and N,N,N-Trimethylethenaminium, and lipid 269 
metabolites, including glycerophospholipids of the cardiolipin (PC) class, and isobutyl decanoate and diethyl 270 
glutarate. Separation between the clinical samples (LC+ and LC- classes) appeared to be due to elevated levels of 271 
metabolites identified as hexanal, cysteic acid, hydroxypyruvic acid, and the cholesterol ester with an acyl group 272 
CE (22:5(4Z,7Z,10Z,13Z,16Z)). The mass-ion 1496.72 showing the highest AUC value (0.85) was identified as the 273 
ganglioside GM1 (18:1/12:0).  274 
  275 
 276 
 277 
 278 
 279 
 280 
 281 
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4 Discussion 282 
 283 
Since the ‘Warburg Effect’ was first described in 1956 [17], the alterations that cells undergo during 284 
carcinogenesis has been a focus of both basic and applied clinical research. To date, the majority of metabolomic 285 
lung cancer studies appear to have focussed on the cancerous tumours themselves or serum from affected 286 
patients, using a limited range of MS techniques [18]. Here, we suggest that the sputum of patients can be used 287 
as a non-invasive source of biomarkers for the identification of LC status. 288 
 289 
Sputum represents a biofluid that could be readily accessed from the target group and the results of this study 290 
indicate it could be used as a biofluid matrix for an efficient LC screen. We used two mass-spectrometry 291 
platforms; the widely employed GC-MS and also FIE-MS on the same sample set to allow comparison of the 292 
discriminatory power of both. These results suggested that derivatisation (in the case of GC-MS) or the wide 293 
range of adducts formed with positive ionisation using FIE-MS (as opposed to negative, ionisation where simple 294 
proton loss [M-—H+] is predominant) can obscure screens of sputum.  295 
 296 
Analyses of FIE-MS- data allowed identification of clinically relevant groupings and both PCA and HCA could 297 
separate a “healthy” control samples from samples taken from clinically-referred patients. Although, not all of 298 
these patients were subsequently confirmed to be LC+, the LC- group had symptoms necessitating referral and 299 
thus, should be considered to be “unwell”. Even at this level, a non-invasive and rapid test of lung health would 300 
be useful to the medical community.  301 
 302 
Random Forest analysis appeared to be particularly effective in discriminating between LC+ and CON samples; 303 
with LC- samples between these extremes. We coupled RF analyses with assessment of ROC using AUC analysis; 304 
which has been widely used to determine the diagnostic value of biomarkers. Here, the False Discovery rate vs. 305 
True Discovery rate compared a series of binary tests between our three sample groups. The CON group was 306 
highly distinctive, with ROC-AUC analyses detecting metabolites with extremely high AUC values. Crucially, a 307 
number of FIE-MS- metabolites that had AUC values greater than 0.80 when comparing LC+/LC, a cut-off for 308 
discrimination that may be useful in a clinical setting were identified.  This equates to a false discovery rate of 309 
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under 20% for these metabolites although care needs to be taken with this figure and it requires confirmation 310 
with external validation datasets to remove any danger of “overfitting” i.e. deriving a model which describes 311 
random error or noise rather than any true relationship.  Our LC+ group consisted of a range of LC stages and 312 
histology, suggesting that biomarkers established through metabolomic profiling techniques could have utility 313 
as a preliminary screen, identifying patients for clinical follow-up for LC confirmation, histology and staging. 314 
 315 
Considering the identities of metabolites separating the CON and LC- class, the increases in putrescine were 316 
interesting because polyamines are essential for normal mammalian cell growth.  Polyamine metabolism is 317 
frequently dysregulated in cancer and has emerged as a target for therapeutic intervention [19]. However, as 318 
polyamines did not discriminate between the CON and LC+ or LC- and LC+ classes, we were not able to associate 319 
these polyamine changes with LC in this study. Therefore, changes in polyamines may have reflected changes 320 
linked to an inflammatory response and/or cell death; which may reflect pathogen attack or polyamine 321 
catabolism which can generate reactive oxygen species (ROS) [20]. 322 
 323 
Also prominent in the clinical samples (LC+/LC-) compared to the CON class were lipid metabolites, including 324 
glycerophospholipids of the cardiolipin (PC) class as well as isobutyl decanoate and diethyl glutarate. Cardiolpins 325 
are major components of the inner mitochondrial and is particularly susceptible to ROS attack due to its high 326 
content of unsaturated fatty acids.  Increased ROS would affect mitochondrial membrane fluidity, possibly 327 
resulting in cardiolipin release and possibly leading to the greater than two fold increases that we have detected 328 
in our study. Cardiolipin-associated changes in membrane fluidity have been associated with reduced 329 
mitochondrial oxidative phosphorylation efficiency and apoptosis [21]. In this context, it is relevant that isobutyl 330 
decanoate and diethyl glutarate, as potential phospholipid fragments, could represent the products of lipid 331 
peroxidation and as they exhibited a 4.69 and 3 fold increase, respectively, in the LC+ class compared to CON.  332 
 333 
Identifying the metabolite changes in the LC+ samples targeted by RF and ROC-AUC, there appeared to be higher 334 
levels of hexanal, cysteic acid, hydroxypyruvic acid, and one metabolite without accurate mass identification, 335 
and eleven metabolites with lower levels. Hexanal has previously been shown to be elevated in blood samples 336 
from lung cancer patients [22], suggesting its validity as a LC biomarker. To our knowledge there have been no 337 
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reports of cysteic acid or hydroxypyruvic acid being targeted as LC biomarkers. These could suggest alterations 338 
in cysteine metabolism (in the case of cysteate) or glycolysis (in the case of the pyruvic acid derivative) are being 339 
targeted in our metabolomic analyses. The potential relevance of the cholesteryl docosapentaenoate; 340 
CE(22:5(4Z,7Z,10Z,13Z,16Z)) is unknown, but its increase could reflect membrane disruption. Of particular 341 
interest was ganglioside GM1 (18:1/12:0) which represents a glycosphingolipid inked to a single sialic acid 342 
through its sugar group. Gangliosides have primarily been studied in neural tissues, but can be found in most 343 
cell types where they are involved in cell–cell recognition, cell–matrix attachment, cell growth and cell 344 
differentiation. Interestingly, ganglioside GM1 has already been associated with LC and particularly with SCLC 345 
due to a tendency to arise from neuroectodermal tissue [23]. Indeed, GM1 ganglioside-fused to hemocyanin 346 
has been used to specifically target SCLC tissue in patients [24]. Cholera toxin which is known to target GM1 347 
ganglioside was found to suppress the growth of 9 out of 15 SCLC cell lines with those resistant to the toxin 348 
exhibiting reduced GM1 ganglioside expression [25]. Taken together with our results, ganglioside GM1 could be 349 
a good candidate for biomarker based LC screens.  350 
 351 
 352 
 353 
 354 
 355 
 356 
 357 
 358 
 359 
 360 
 361 
 362 
 363 
 364 
 365 
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5 Conclusions 366 
 367 
As far as we can ascertain, this is the first study to report on the metabolomic profiling of sputum acquired from 368 
LC patients. The use of sputum, the production of which is symptomatic of LC, as a biofluid for screening carries 369 
the benefit of being non-invasive, high-throughput, and low-cost, compared to current conventional methods 370 
such as CT scan [26]. It may be that a combination of metabolomic biomarkers and other types, such as 371 
circulating miRNAs, would allow for an integrated approach to LC screening, as has been suggested for other 372 
cancers [27]. Here, we have shown the power of using metabolomics to identify biomarkers with potential 373 
clinical application for LC. Further work, using a larger patient cohort, will be required to ascertain the utility of 374 
metabolomic biomarkers for LC stage and histological subtype. 375 
 376 
 377 
 378 
 379 
 380 
 381 
 382 
 383 
 384 
 385 
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 387 
 388 
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 390 
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Tables and Legends 506 
 507 
Table 1 | Summarised Patient and Participant Information 508 
Summarised patient information detailing clinical data. Full clinical data for clinically acquired samples, and 509 
information collected for healthy control participants, are fully detailed in Supplementary Table 1. 510 
 511 
 Non-Clinical Controls (CON) LC Negative (LC-) LC Positive (LC+) 
Number 33 11 23 
Age 55.3 (14.6) 66.5 (14.3) 66.6 (8.1) 
Gender    
Male 20 10 11 
Female 13 1 12 
Smoking Status    
Current 15 3 10 
Ex 0 8 10 
Never 18 0 3 
Smoking Pack Years NC 49.0 (34.9) 39.3 (18.9) 
Infection Present    
Yes NC 3 1 
No NC 8 22 
CO Level (ppm) NC 3.7 (1.3) 4.2 (2.8) 
 512 
 513 
 514 
 515 
 516 
 517 
 518 
 519 
 520 
 521 
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Table 2 | Top Five Area Under Curve Values for Negative FIE-MS Mode Metabolites 523 
Using the online ROCCET platform, the top five metabolites, based on AUC values, for each differential group 524 
comparison were identified. For clinical and non-clinical comparisons, high AUC values were obtained, and for 525 
the LC negative and positive comparison, a number of metabolites were identified with AUC values greater than 526 
0.8. AUC range refers to the 95% confidence intervals of the true AUC value as given by the ROCCET platform. 527 
 528 
Differential Metabolite AUC 
Value 
True AUC 
Range 
t-Test Fold 
Change 
CON 
Vs 
LC- 
N,N,N-Trimethylethenaminium 
/CL(16:1(9Z)/18:1(11Z)/16:1(9Z)/18:1(9Z))  1.00 
0.989 - 1.000 4.47 x 10
-15 -2.38 
N,N,N-Trimethylethenaminium /1560.81 1.00 0.983 – 1.000 3.10 x 10-15 -2.26 
Putrescine/CL(16:1(9Z)/18:1(11Z)/16:1(9Z)/18:1(9Z))  0.99 0.975 – 1.000 6.09 x 10-15 -2.25 
Putrescine/1560.81 0.99 0.975 – 1.000 3.64 x 10-15 -2.14 
53.27/1209.45 0.99 0.967 – 1.000 1.79 x 10-14 -2.28 
LC+ 
Vs 
CON 
53.27/Isobutyl decanoate 1.00 0.993 – 1.000 8.74 x 10-24 4.71 
Putrescine/Isobutyl decanoate 1.00 0.992 – 1.000 7.42 x 10-24 4.69 
189.09 1.00 0.987 – 1.000 6.12 x 10-20 2.57 
Diethyl glutarate  0.99 0.979 – 1.000 1.42 x 10-18 3.00 
Cysteamine 0.99 0.980 – 1.000 3.03 x 10-20 2.35 
LC+ 
Vs 
LC - 
Ganglioside GM1 (18:1/12:0) 0.85 0.709 – 0.953 2.93 x 10-3 -0.03 
957.36 0.83 0.680 – 0.953 4.57 x 10-3 0.31 
1382.45 0.83 0.668 – 0.957 5.93 x 10-4 0.07 
CE(22:5(4Z,7Z,10Z,13Z,16Z))  0.82 0.644 – 0.947 1.28 x 10-2 0.00 
1434.00 0.81 0.621 – 0.947 9.84 x 10-4 0.14 
 529 
 530 
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Figures 531 
 532 
Figure 1 | Principal Component Analysis Plots for FIE-MS and GC-MS Metabolites 533 
PCA, based on metabolites acquired in (a) FIE-MS negative mode, (b) FIE-MS positive mode, and (c) GC-MS, 534 
clearly differentiates between the clinically and non-clinically acquired samples, though separation of the two 535 
clinical groups, lung cancer and symptom controls, does not occur. For (c), coordinate markers are means of 536 
individually calculated coordinates from duplicate GC-MS runs. 537 
 538 
 539 
 540 
 541 
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Figure 2 |Hierarchical Cluster Analysis with Heat Mapping for Negative Ionisation FIE-MS 542 
Hierarchical cluster analysis and corresponding heat maps were constructed, based on the top 25 metabolites 543 
identified through one-way ANOVAs, for metabolites identified in FIE-MS negative ionisation mode. Similarly to 544 
PCA plots, separation between the clinically and non-clinically acquired samples was clear, but separation 545 
between LC positive and negative samples was not evident. 546 
 547 
 548 
 549 
 550 
 551 
 552 
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Figure 3| Random Forest Plots for Identification of Key FIE-MS Metabolites 554 
Random forests plots were constructed, using MetaboAnalyst 2.0 for negative ionisation FIE-MS mode, which 555 
revealed a number of metabolites which may have potential in terms of diagnostic markers, particularly those 556 
that are either higher or lower in the LC positive group. 557 
 558 
 559 
 560 
 561 
 562 
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 565 
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 567 
 568 
 569 
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Figure 4| Univariate Receiver Operating Characteristic Curve Analyses for Biomarker Identification 571 
Using the online facility, ROCCET, univariate receiver operating characteristic curves (ROC) were created, and 572 
plotted to create area under the curve (AUC) figures for metabolites identified in negative ionisation FIE-MS 573 
mode. The metabolite with the highest AUC value for each differential group is plotted. 574 
 575 
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